Stock Events

Stock Events

Atara Biotherapeutics 

$9.76
95
+$0.23+2.41% 20:00 Today
+$0.00+0%20:00After hours

Statistics

Day High
9.94
Day Low
9.25
52W High
19.15
52W Low
3.92
Volume
132,728
Avg. Volume
65,782
Mkt Cap
97.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.86
-0.74
1.38
3.5
Expected EPS
-0.132775
Actual EPS
N/A

Financials

27.07%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
120.77MRevenue
32.69MNet Income

Analyst Ratings

11.50Average Price Target
The highest estimate is 13.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATRA. It's not an investment recommendation.
Amazon
17
AMZN
Microsoft
16
MSFT
Apple
14
AAPL
NVIDIA
14
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics is involved in the development of allogeneic CAR-T therapies, directly competing with Atara's allogeneic T-cell immunotherapy approach.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T and T-cell receptor (TCR) therapy space, similar to Atara's focus areas.
Novartis
NVS
Mkt Cap292.35B
Novartis is a major player in the CAR-T therapy market with Kymriah, competing in the same space as Atara's T-cell immunotherapy products.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has investments in CAR-T and other immunotherapies, positioning it as a competitor in the broader immunotherapy market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on innovative therapies and investments in immuno-oncology position it as a competitor in the immunotherapy and cell therapy markets.

About

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Show more...
CEO
Anhco Nguyen
Employees
10
Country
United States
ISIN
US0465132068
WKN
000A40DQJ

Listings

MU
DE
AT2.MU
STU
DE
AT20.STU
F
DE
AT20.F
XNAS
US
ATRA

0 Comments

Share your thoughts

FAQ

What is Atara Biotherapeutics stock price today?▼
The current price of ATRA is $9.76 USD — it has increased by +2.41% in the past 24 hours. Watch Atara Biotherapeutics stock price performance more closely on the chart.
What is Atara Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Atara Biotherapeutics stocks are traded under the ticker ATRA.
Is Atara Biotherapeutics stock price growing?▼
ATRA stock has risen by +6.09% compared to the previous week, the month change is a +11.29% rise, over the last year Atara Biotherapeutics has showed a -23.75% decrease.
What is Atara Biotherapeutics market cap?▼
Today Atara Biotherapeutics has the market capitalization of 97.97M
When is the next Atara Biotherapeutics earnings date?▼
Atara Biotherapeutics is going to release the next earnings report on October 29, 2026.
What were Atara Biotherapeutics earnings last quarter?▼
ATRA earnings for the last quarter are -0.32 USD per share, whereas the estimation was -0.32 USD resulting in a -1.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Atara Biotherapeutics revenue for the last year?▼
Atara Biotherapeutics revenue for the last year amounts to 120.77M USD.
What is Atara Biotherapeutics net income for the last year?▼
ATRA net income for the last year is 32.69M USD.
How many employees does Atara Biotherapeutics have?▼
As of September 04, 2026, the company has 10 employees.
In which sector is Atara Biotherapeutics located?▼
Atara Biotherapeutics operates in the Health & Wellness sector.
When did Atara Biotherapeutics complete a stock split?▼
The last stock split for Atara Biotherapeutics was on June 20, 2024 with a ratio of 1:25.
Where is Atara Biotherapeutics headquartered?▼
Atara Biotherapeutics is headquartered in THOUSAND OAKS, United States.